Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mirvetuximab soravtansine plus Bevacizumab

Phase 3Antibody–drug conjugate

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epithelial OvarianRecruiting

Epithelial OvarianPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2032

Phase 3Recruiting

Epithelial Ovarian

NCT05445778

Clinical

Trials by Indication[1]

Epithelial Ovarian1 trial

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT05445778·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mirvetuximab soravtansine plus Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirvetuximab soravtansine plus Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirvetuximab soravtansine plus Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Related News